Following her discovery that certain tumors appear on MRI before clinical diagnosis, Dr. Debbie Anabi began developing an AI-based technology capable of identifying these early lesions. Through a collaboration between Pinkstar and the Meirav Breast Center, this effort aims to improve early breast cancer detection
Sheba Medical Center’s Department of Ophthalmology completed a collaborative clinical mission in Accra, Ghana, working closely with the medical staff of Korle Bu Teaching Hospital to deliver patient evaluations, complex surgeries, and hands-on training.
On October 13, 2025, Israel witnessed a day that will never be forgotten. The last twenty living Israeli hostages were finally returned home after more than two years in captivity. Across the country, people sat in front of screens at home and at work, holding their breath as they waited to see their loved ones come home. It was a day filled with both fear and hope — fear of what the hostages had endured and of the long recovery ahead, and hope that, together, we will heal and rebuild.
In September 2025, Dr. Tiran Golani, Ophthalmology Resident at the Goldschleger Eye Institute, attended the European Society of Cataract and Refractive Surgeons (ESCRS) Conference in Copenhagen. Representing Sheba Global Ophthalmology, she presented research conducted alongside Dr. Hostovsky and colleagues at Sheba Global Ophthalmology.
More than 300 healthcare professionals from 34 countries joined Sheba Medical Center’s webinar on CAR T-cell therapy, offered as part of a research program for autoimmune diseases. Led by Prof. Merav Lidar and Prof. Elad Jacoby, the session explored new clinical possibilities, shared emerging research, and fostered international dialogue on one of medicine’s cutting-edge treatment frontiers.
A groundbreaking three-year partnership bringing together NVIDIA, Sheba’s ARC Innovation Center, and the Icahn School of Medicine at Mount Sinai was announced on November 18, 2025. The partnership aims to harness artificial intelligence (AI) through large language models (LLMs) to decode the 98% of the human genome that remains unexplored, paving the way for novel approaches in disease prevention, diagnosis, and precision medicine worldwide.
